• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Mobic (meloxicam) Tablets, Oral Suspension

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – July 2011


Summary View


7.8 Kayexalate (sodium polystyrene sulfonate)
  • Cases of intestinal necrosis (possibly fatal) have been described in patients who received concomitant sorbitol and Kayexalate (sodium polystyrene sulfonate). Due to the presence of sorbitol in MOBIC Oral Suspension, use with Kayexalate is not recommended